NCT05014334View on ClinicalTrials.gov

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

PHASE4CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

June 30, 2022

Conditions

Helicobacter Pylori InfectionChronic Gastritis

Interventions

DRUG

Berberine

berberine 500 mg, twice daily for 14 days

DRUG

Vonoprazan

Vonoprazan 20 mg, twice daily for 14 days

DRUG

Amoxicillin

amoxicillin 1000mg, twice daily for 14 days.

DRUG

Rabeprazole

Rabeprazole 10mg, twice daily for 14 days.

DRUG

Bismuth

Bismuth 220mg, twice daily for 14 days.

DRUG

Clarithromycin

clarithromy 500mg, twice daily for 14 days.

Trial Locations (1)

710032

Xijing Hosipital of Digestive Disease, Xi'an

All Listed Sponsors

lead

Xijing Hospital of Digestive Diseases

OTHER

NCT05014334 - Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication | Biotech Hunter | Biotech Hunter